Short-Term Improvement in Chronic Pain for Oral Cannabinoids
Oral synthetic cannabinoid products with high tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratios are associated with moderate short-term improvement in chronic pain.
Oral synthetic cannabinoid products with high tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratios are associated with moderate short-term improvement in chronic pain.
David Dickerson, MD, chair of the ASA Committee on Pain Medicine, discusses suggested changes and recommendations to the proposed clinical practice guidelines for prescribing opioids that were recently issued by the CDC.
Mailed at-home disposal kits increase self-reported opioid disposal rates after common surgical procedures.
A large, sustained reduction in opioid prescribing by emergency clinicians is possible through an intervention using direct, personalized feedback to clinicians and an electronic dashboard for peer comparison.
State laws are associated with small and non-statistically significant changes in opioid prescribing or nonopioid pain treatment.
A mindfulness intervention can lead to greater sustained improvements in opioid misuse and chronic pain symptoms than supportive group psychotherapy.
Settlements totaling $26 billion have been finalized between drugmaker Johnson & Johnson plus three major pharmaceutical distributors and state and local governments over the companies’ role in America’s opioid crisis.
Fundamental reform of regulatory systems is needed to address the opioid crisis in North America and beyond.
Schools should stock the opioid overdose antidote naloxone and train staff and students how to respond to an overdose, experts say after the apparent fentanyl overdose death of a seventh grader at a school in Hartford, Connecticut.
There was a decrease in nonpharmacologic therapy and an increase in opioid prescription during the COVID-19 pandemic versus 2019.